Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Total Non-Current Liabilities (2018 - 2021)

Cue Biopharma (CUE) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $17.9 million as the latest value for Q4 2021.

  • Quarterly Total Non-Current Liabilities fell 4.15% to $17.9 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $17.9 million through Dec 2021, down 4.15% year-over-year, with the annual reading at $17.9 million for FY2021, 4.15% down from the prior year.
  • Total Non-Current Liabilities hit $17.9 million in Q4 2021 for Cue Biopharma, up from $16.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $18.7 million in Q4 2020 to a low of $3.0 million in Q2 2018.
  • Historically, Total Non-Current Liabilities has averaged $13.2 million across 4 years, with a median of $15.1 million in 2019.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 408.1% in 2019 and later decreased 20.85% in 2020.
  • Year by year, Total Non-Current Liabilities stood at $6.2 million in 2018, then skyrocketed by 109.16% to $13.0 million in 2019, then skyrocketed by 43.69% to $18.7 million in 2020, then dropped by 4.15% to $17.9 million in 2021.
  • Business Quant data shows Total Non-Current Liabilities for CUE at $17.9 million in Q4 2021, $16.7 million in Q2 2021, and $17.7 million in Q1 2021.